Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season (GOS)

August 1, 2012 updated by: University of Florida

Protocol 2: Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season

The purpose of this research study is to determine whether a functional fiber, galactooligosaccharide, can help maintain immune strength and digestive health in free-living older adults. It is hypothesized that older adults consuming the fiber daily for 24 weeks over cold and flu season will have more healthy days due to a proliferation of beneficial bacteria within the colon which alters cytokine production and enhances natural killer cell function. Immune and gastrointestinal health will be evaluated via daily questionnaires obtained from 80 participants and from the collection of blood and fecal samples.

Study Overview

Detailed Description

A prospective, randomized, parallel, double-blind, placebo controlled trial will be used. Healthy older adults will be recruited from the Gainesville area via direct mailing, flyers, list servs, presentations to clubs/organizations/church groups, social networks, etc. Informed consent will be obtained and once the informed consent is signed the inclusion/exclusion form will be reviewed to determine whether a subject qualifies for the study.

Prior to randomization, height, weight, age, and a stool sample will be obtained. On the day of randomization, blood will be drawn and saliva will be collected for baseline immune function studies from all subjects who qualify based on the final criteria (i.e., cannot have a cold on the day of randomization).

Subjects will be stratified based on body mass index and age and randomized via sealed envelope to the treatment (5 g GOS) or placebo groups (n=40/group). The fiber will be provided in small packets containing 2.5 g of fiber and 2.5 g sucrose (treatment) or 5 g of sucrose (placebo). Subjects will be instructed to add the contents of the packet to coffee, tea, water, milk, or other non-carbonated drink, hot cereal or pudding and mix well. Subjects will be told to consume two packets per day and maintain a daily study log. The daily questionnaire will ask about intake of the fiber, cold symptoms, and general health (i.e., new medications, doctor visits).

Between weeks two and three of the intervention, a second stool sample will be obtained. After three weeks of the intervention, subjects will receive the influenza vaccination and blood and saliva will be collected for immune function studies. Two weeks postvaccination (i.e., 5 weeks of intervention), blood and saliva will be collected for immune function studies. Subjects will continue the intervention and maintain daily logs for a total of 24 weeks. Subjects will also be asked to complete a questionnaire on a monthly basis regarding gastrointestinal symptoms and typical level of exercise.

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32611
        • University of Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

56 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 60 years of age or older
  • willing to complete daily and monthly questionnaires
  • willing to receive the fall influenza vaccination as part of the study protocol
  • willing to provide 3 blood samples, 3 saliva samples, and 2 stool samples and answer a food frequency questionnaire over the course of the study
  • willing to discontinue any immune-enhancing dietary supplements ( e.g., prebiotics and fiber supplements, probiotics, echinacea, fish oil, vitamin E >100% of the RDA or >15 mg/day)
  • willing to take the study fiber for 24 weeks
  • willing to provide a social security number to receive study payment Note: the subject can still participate if unwilling to provide SS#, but no financial reimbursement can be provided.
  • had a cold in the last 12 months
  • able to take foods and the study fiber without the aid of another person.
  • eligible and willing to receive the influenza vaccine for the current year. That is, you cannot have already received an influenza vaccine for the 2010/2011 season prior to receiving it from the study

Exclusion Criteria:

  • current smoker
  • chronic allergies involving the upper respiratory tract (Chronic = taking allergy medicine daily)
  • taking any medication for constipation or diarrhea
  • currently taking any anti-inflammatory drugs on a regular basis
  • currently treated for Alzheimer's disease
  • allergy to milk or a serious allergy to eggs (note lactose intolerance should not be a problem because 1 fiber packet contains only 0.3 g of lactose whereas 1 cup of milk contains 12.8 g of lactose)
  • currently being treated for any known illnesses or conditions that may impact perceived health such as HIV/AIDS, immune modulating diseases (autoimmune, hepatitis, cancer, etc.), diabetes, kidney disease, gastrointestinal diseases (gastric ulcers, Crohn's, ulcerative colitis, etc.)
  • received chemotherapy or other immune suppressing therapy within the last year
  • received antibiotic therapy in the past two months
  • receiving supplemental oxygen

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Sugar Pill
5 g of sucrose twice daily for 24 weeks
Experimental: Galactooligosaccharide 5 g
2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of days without cold/flu symptoms
Time Frame: Measured Daily for 24 weeks
  • Average number of cold symptoms [Nasal Symptoms (Running Nose, Stuffed nose, Blowing the Nose, Yellow Secretion, Bloody Secretion), Pharyngeal Symptoms (Scratchy Throat, Sore Throat, Hoarseness), Bronchial Symptoms (Cough, Secretion, Yellow Secretion), Headache, Achiness (Muscle Pain), Conjunctivitis (Reddish Eyes), Fatigue, Ear Discomfort and Stiffness/Chills]
  • Average sum of symptom intensity
  • Cold symptom score (sum of symptom intensity scores)
Measured Daily for 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Digestive Health
Time Frame: Measured Monthly for 24 weeks
  • Symptoms (gas, bloating, diarrhea, etc.)
  • Bowel habits (bowel movement frequency and consistency)
Measured Monthly for 24 weeks
Immune Function
Time Frame: Measured at baseline, week 3 and week 5 of the intervention
  • Leukocyte phenotype and function
  • Peripheral blood mononuclear cell cytokine production to mitogens
  • Serum acute phase proteins, cytokines, endotoxin, and immunoglobulin
  • Salivary and fecal sIgA
Measured at baseline, week 3 and week 5 of the intervention
Microbiota Study
Time Frame: Measured at baseline and between weeks 2 and weeks 3 of intervention
  • Microbial diversity measured by DGGE profiling (detect large distortions)
  • qPCR to quantify changes in Lactic Acid Bacteria and Bifidobacteria (beneficial changes)
  • 16S rRNA sequencing (454) to identify treatment effects on specific bacteria
Measured at baseline and between weeks 2 and weeks 3 of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

April 1, 2011

Study Completion (Actual)

April 1, 2011

Study Registration Dates

First Submitted

February 22, 2011

First Submitted That Met QC Criteria

February 23, 2011

First Posted (Estimate)

February 24, 2011

Study Record Updates

Last Update Posted (Estimate)

August 2, 2012

Last Update Submitted That Met QC Criteria

August 1, 2012

Last Verified

July 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • 355-2010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Sucrose

Subscribe